Report
Boltz says it raised $110M for AI-powered biomolecular design
The company reports 50-fold molecular token usage growth since June and partnerships with six top-20 pharmaceutical companies.
TLDR
According to Boltz’s announcement, Bessemer led the $110 million Series A to broaden access to AI-powered biomolecular design. JorgeCondeBio describes Boltz’s molecular tokens as intelligence scientists can buy and use on demand, calling AI a “consumable reagent” for drug discovery.
Combined views
22.5K
4 Sources, first seen ago
Comments